Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data

BACKGROUND: Reslizumab is an anti-interleukin 5 monoclonal antibody that has demonstrated to reduce the risk of severe exacerbations and to improve symptoms, lung function, and quality of life in randomized controlled trials that included patients with severe eosinophilic uncontrolled asthma (SEUA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez de Llano, Luis A, Cosío, Borja G, Lobato Astiárraga, Ignacio, Soto Campos, Gregorio, Tejedor Alonso, Miguel Ángel, Marina Malanda, Nuria, Padilla Galo, Alicia, Urrutia Landa, Isabel, Michel de la Rosa, Francisco J, García-Moguel, Ismael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765543/
https://www.ncbi.nlm.nih.gov/pubmed/35058696
http://dx.doi.org/10.2147/JAA.S340562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765543/
https://www.ncbi.nlm.nih.gov/pubmed/35058696
http://dx.doi.org/10.2147/JAA.S340562

Ejemplares similares